Literature DB >> 21449674

Systems pharmacology assessment of the 5-fluorouracil pathway.

Filipe A Muhale1, Barbara A Wetmore, Russell S Thomas, Howard L McLeod.   

Abstract

AIM: To assess the impact of the 5-fluorouracil (5-FU) drug-pathway genes on cytotoxicity, and determine whether loss-of-function analyses coupled with functional assays can help prioritize pharmacogenomic candidate genes. MATERIALS &
METHODS: Dose-response experiments were used to quantify the phenotype of sensitivity to 5-FU following the specific knockdown of genes selected from the 5-FU PharmGKB drug pathway in three human colorectal cell lines. Changes in sensitivity were considered significant if the IC(50) for shRNA-exposed cells were three standard deviations outside the mean IC(50) for control-treated cells.
RESULTS: Of the 24 genes analyzed, 13 produced significant changes on the phenotype of sensitivity to 5-FU (DHFR, DPYS, DTYMK, DUT, FPGS, GGH, NME1, NT5C, RRM1, TYMS, UCK2, UNG and UMPS).
CONCLUSION: The RNAi screening strategy enabled prioritization of the genes from the 5-FU drug pathway. Further validation of the genes credentialed in this study should include gene activity or expression and mutation analyses of clinical samples.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21449674      PMCID: PMC3124653          DOI: 10.2217/pgs.10.188

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  42 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

2.  Structural organization of the human dihydropyrimidine dehydrogenase gene.

Authors:  M R Johnson; K Wang; S Tillmanns; N Albin; R B Diasio
Journal:  Cancer Res       Date:  1997-05-01       Impact factor: 12.701

3.  Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer.

Authors:  Elizabeth A Kidd; Jinsheng Yu; Xia Li; William D Shannon; Mark A Watson; Howard L McLeod
Journal:  Clin Cancer Res       Date:  2005-04-01       Impact factor: 12.531

4.  Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy.

Authors:  Christiane Jakob; Torsten Liersch; Wolfdietrich Meyer; Gustavo B Baretton; Peter Häusler; Wolfgang Schwabe; Heinz Becker; Daniela E Aust
Journal:  Am J Surg Pathol       Date:  2005-10       Impact factor: 6.394

5.  Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.

Authors:  C G Leichman; H J Lenz; L Leichman; K Danenberg; J Baranda; S Groshen; W Boswell; R Metzger; M Tan; P V Danenberg
Journal:  J Clin Oncol       Date:  1997-10       Impact factor: 44.544

6.  Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients.

Authors:  Tian-Li Wang; Luis A Diaz; Katharine Romans; Alberto Bardelli; Saurabh Saha; Gennaro Galizia; Michael Choti; Ross Donehower; Giovanni Parmigiani; Ie-Ming Shih; Christine Iacobuzio-Donahue; Kenneth W Kinzler; Bert Vogelstein; Christoph Lengauer; Victor E Velculescu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-17       Impact factor: 11.205

7.  Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism.

Authors:  Holly R Thomas; Hany H Ezzeldin; Vincenzo Guarcello; Lori K Mattison; Brooke L Fridley; Robert B Diasio
Journal:  Pharmacogenet Genomics       Date:  2008-01       Impact factor: 2.089

8.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

Authors:  Jolien Tol; Miriam Koopman; Annemieke Cats; Cees J Rodenburg; Geert J M Creemers; Jolanda G Schrama; Frans L G Erdkamp; Allert H Vos; Cees J van Groeningen; Harm A M Sinnige; Dirk J Richel; Emile E Voest; Jeroen R Dijkstra; Marianne E Vink-Börger; Ninja F Antonini; Linda Mol; Johan H J M van Krieken; Otilia Dalesio; Cornelis J A Punt
Journal:  N Engl J Med       Date:  2009-02-05       Impact factor: 91.245

Review 9.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

10.  Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.

Authors:  James Cassidy; Leonard B Saltz; Bruce J Giantonio; Fairooz F Kabbinavar; Herbert I Hurwitz; Ulrich-Peter Rohr
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-11       Impact factor: 4.553

View more
  16 in total

Review 1.  Pharmacologic resistance in colorectal cancer: a review.

Authors:  William A Hammond; Abhisek Swaika; Kabir Mody
Journal:  Ther Adv Med Oncol       Date:  2016-01       Impact factor: 8.168

2.  Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer.

Authors:  Wenqi Bai; Yueqin Wu; Ping Zhang; Yanfeng Xi
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 3.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 4.  The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed.

Authors:  Jorge Hernando-Cubero; Ignacio Matos-García; Vicente Alonso-Orduña; Jaume Capdevila
Journal:  J Gastrointest Cancer       Date:  2017-06

5.  Delimiting Allelic Imbalance of TYMS by Allele-Specific Analysis.

Authors:  Emilia Balboa-Beltrán; Raquel Cruz; Angel Carracedo; Francisco Barros
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

6.  Differential nucleobase protection against 5-fluorouracil toxicity for squamous and columnar cells: implication for tissue function and oncogenesis.

Authors:  John P Vanden Heuvel; Jerry T Thompson; Prajakta Albrecht; Donald Mandetta; Harry Kamerow; John P Ford
Journal:  Invest New Drugs       Date:  2015-07-01       Impact factor: 3.850

7.  Overexpression of Uridine-Cytidine Kinase 2 Correlates with Breast Cancer Progression and Poor Prognosis.

Authors:  Guosong Shen; Pingya He; Yingying Mao; Peipei Li; Frank Luh; Guohui Ding; Xiyong Liu; Yun Yen
Journal:  J Breast Cancer       Date:  2017-06-26       Impact factor: 3.588

8.  High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer.

Authors:  Nathaniel Melling; Masoud Rashed; Cornelia Schroeder; Claudia Hube-Magg; Martina Kluth; Dagmar Lang; Ronald Simon; Christina Möller-Koop; Stefan Steurer; Guido Sauter; Frank Jacobsen; Franziska Büscheck; Corinna Wittmer; Till Clauditz; Till Krech; Maria Christina Tsourlakis; Sarah Minner; Hartwig Huland; Markus Graefen; Lars Budäus; Imke Thederan; Georg Salomon; Thorsten Schlomm; Waldemar Wilczak
Journal:  Int J Mol Sci       Date:  2017-01-29       Impact factor: 5.923

9.  Uridine-cytidine kinase 2 promotes metastasis of hepatocellular carcinoma cells via the Stat3 pathway.

Authors:  Qiming Zhou; Hai Jiang; Jianlong Zhang; Wei Yu; Zhenyu Zhou; Pinbo Huang; Jie Wang; Zhiyu Xiao
Journal:  Cancer Manag Res       Date:  2018-11-26       Impact factor: 3.989

10.  Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.

Authors:  Oluf Dimitri Røe; Adam Szulkin; Endre Anderssen; Arnar Flatberg; Helmut Sandeck; Tore Amundsen; Sten Even Erlandsen; Katalin Dobra; Stein Harald Sundstrøm
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.